GMPharma Consult ApS: Financial statements 2023
CVR: 42760137
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
GMPharma Consult ApS (CVR 42760137) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -14,202 and a net result of DKK -12,843. Equity in the 2023 report amounted to DKK 127,664. The solvency ratio was 76.7%.
- Revenue
- DKK 0
- Gross Profit
- DKK -14,202
- Profit/Loss
- DKK -12,843
- Equity
- DKK 127,664
- Total Assets
- DKK 166,458
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
GMPharma Consult ApS has published its interim report for the period October 1, 2021 – December 31, 2022.
About GMPharma Consult ApS
GMPharma Consult ApS is a Danish company of the type Anpartsselskab based in Hillerød, founded in 2021. The company is registered under the industry Anden teknisk rådgivning. The management consists of Ina Maria Carolina Glamheden-Helle. The company is owned by Startplattan 192299 Aktiebolag. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -11,057 and a net result of DKK -29,176 compared with DKK -39,429 the year before. Equity in the 2025 report amounted to DKK 59,058.